Clearside Biomedical is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®).

The platform provides an in-office, repeatable, non-surgical procedure, offering targeted and compartmentalized delivery to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Our suprachoroidal injection technology can be used in conjunction with existing drugs designed for the SCS, novel therapies, and future therapeutic innovations. We are developing a pipeline of small molecule product candidates for administration via our SCS Microinjector®, and we are also looking to strategically partner with companies utilizing other ophthalmic therapeutic innovations. We believe our proprietary suprachoroidal administration platform has the potential to become a standard for delivery of therapies intended to treat chorioretinal diseases.


Clearside’s Suprachoroidal Space (SCS®) Injection Platform

Clearside’s proprietary SCS injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform is inherently flexible and intended to work with established medications, new formulations of medicines, as well as future innovations, that can be delivered via suprachoroidal administration.


We are leveraging our SCS injection platform by building an internal research and development pipeline and by creating external collaborations with other companies.


Our extensive patent portfolio provides us with exclusive rights to commercialize pharmacological agents for treatment of eye diseases via suprachoroidal injection. Our drug candidates, SCS Microinjector and method of drug administration into the SCS are protected by multiple U.S., European and international patents broadly directed to the use of the device, administration of any drug into the SCS by injection, as well as specific product candidates.